In advanced dry disease, a key problem is failure of retinal pigment epithelium, often shortened to RPE. These cells help ...

Companies across the globe are diligently working toward developing novel Dry Age Macular Degeneration treatment therapies ...

GlobalData is the parent company of Clinical Trials Arena. "Ocugen sets sights on Phase III after GA gene therapy win" was ...

Scientists at USC are launching a new trial to test a tiny stem cell implant that could restore vision in people with ...

Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may ...

An editorial published today in The New England Journal of Medicine (NEJM) writes that Science Corporation's PRIMA implant is the first treatment in clinical trials to successfully restore functional ...

Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious ...

Ollin Biosciences has announced positive topline results from its randomized, head-to-head Phase 1b JADE clinical study ...

Medically reviewed by Christine L. Larsen, MD Key Takeaways Macular degeneration is a common eye disease, affecting more than 19 million people in the United States alone.The condition can reduce a ...

Subretinal transplantation of retinal pigment epithelium derived from human embryonic stem cells (hESCs) appears to be a well-tolerated means of treating age-related macular degeneration and Stargardt ...

A novel treatment that uses a disintegrating matrix for sustained release of medication led to improvement in vision and reduced supplemental treatment in patients with diabetic macular edema, ...

The longest living vertebrate on Earth may have a thing or two to teach us about maintaining our eyesight into old age. New ...